Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Vincristine

Vincristine

Vincristine is a chemotherapeutic agent derived from the periwinkle plant, Vinca rosea.
It is used in the treatment of a variety of cancers, including leukemia, lymphoma, and solid tumors.
Vincristine works by disrupting the mitotic spindle, leading to cell cycle arrest and apoptosis.
Effective use of vincristine requires careful dosing and monitoring to balance its therapeutic benefits and potential side effects, which can include neurotoxicity, myelosuppression, and constipation.
Researchers can leverage PubCompare.ai to optimize their vincristine research by identifying the most effective protocols and produts from the scientific literature, pre-prints, and patents - enhancing reproducibility and accuracy.
This AI-driven platform enables powerfull comparisons to uncover new insights and drive vincristine research forward.

Most cited protocols related to «Vincristine»

1
Newly Diagnosed Multiple Myeloma Patients
Cited 64 times
A total of 4445 NDMM patients were enrolled in 11 international, multicentre clinical trials, from 2005 to 2012 (Table S2). The results of these trials were previously reported (clinicaltrials.gov: NCT01346787, NCTC00551928, NCT01091831, NCT01093196, NCT01190787, NCT01063179, NCT01134484, NCT00461747, NCT00200681; Eudract: 2005-004714-32; Netherlands Trial Register: NTR213).14 (link)–24 (link) Patients gave written informed consent before entering the source trials, which were performed in accordance with the Declaration of Helsinki.
All patients received new drugs [immunomodulatory agents (IMIDs) or proteasome inhibitors (PIs)] in association with conventional chemotherapy as upfront treatment or incorporated into pre-transplant induction or post-transplant maintenance strategies, except for the patients enrolled in IFM 2005-01 trial who were randomized to vincristine-adriamicyn-dexamethasone (VAD) induction and VAD-dexamethasone-cyclophosfamide-etoposide-cisplatin before ASCT (Table S3). Baseline data collected included: age, gender, ISS stage, CA detected by iFISH and serum LDH level. Data about ISS stage, CA by FISH and serum LDH were simultaneously available in 3060/4445 patients. The primary endpoint was OS, defined as the time from start of treatment until death due to any cause, or until the last date the patient was known to be alive. The secondary endpoint was progression-free survival (PFS), defined as the time from start of treatment until progression or death due to any cause, or until the last date the patient was known to be progression-free.
Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L., Richardson P., Caltagirone S., Lahuerta J.J., Facon T., Bringhen S., Gay F., Attal M., Passera R., Spencer A., Offidani M., Kumar S., Musto P., Lonial S., Petrucci M.T., Orlowski R.Z., Zamagni E., Morgan G., Dimopoulos M.A., Durie B.G., Anderson K.C., Sonneveld P., San Miguel J., Cavo M., Rajkumar S.V, & Moreau P. (2015). Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 33(26), 2863-2869.
Publication 2015
Dexamethasone Disease Progression Fishes Gender Grafts Immunomodulating Agents Immunomodulatory IMiD Drugs Patients PE regimen Pharmaceutical Preparations Pharmacotherapy Proteasome Inhibitor Serum Vincristine
2
Quantitative Live Cell Cytotoxicity Assay
Cited 21 times
The DIMSCAN system uses digital image fluorescence microscopy to quantify live cells, which selectively accumulate FDA. It is capable of measuring cytotoxicity over a 4-log dynamic range, after digital-image thresholding and eosin-Y quenching [7 (link), 30 (link)]. Cell lines were seeded in 150 μl of complete medium at 700 – 8,000 cells per well (dependent on cell size and doubling time) in 96-well plates. After overnight incubation, drugs were added as single agents in 100 μl of complete medium to the cells, at the following concentrations: 0.003–10 nM for vincristine, 0.01–100 μM for melphalan and etoposide, and 0.01–100 nM for rapamycin. Stock solutions of melphalan and etoposide were prepared at 10 mM in DMSO; vincristine at 1 mM in normal saline; rapamycin 1 mM in DMSO. Controls were treated with the appropriate drug vehicles (DMSO for etoposide, melphalan and rapamycin: final DMSO content of ≤0.1% at the highest concentration tested). Six replicate wells were tested per concentration as well as per control. Following 4 days (96 h) of incubation, 50 μl of 0.5% eosin-Y + 10 μg/ml of FDA were added to the wells. After 20 minutes of incubation in the dark, the fluorescence of viable cells in each well was measured using the DIMSCAN system. The results were expressed as the survival fraction of treated cells for each concentration relative to the control cells. The standard deviations (sd) for control wells were less than 15%, and for any plates in which the sd exceeded 15%, the assay was repeated.
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J, & Reynolds C.P. (2010). National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. Pediatric blood & cancer, 56(2), 239-249.
Publication 2010
Biological Assay Cell Lines Cells Cell Survival Cytotoxin DNA Replication Eosin Etoposide Fluorescence Melphalan Microscopy, Fluorescence Normal Saline Pharmaceutical Preparations Pharmaceutical Vehicles Sirolimus Sulfoxide, Dimethyl Vincristine
3
Methotrexate Therapy for Pediatric Leukemia
Cited 16 times
Patients who consented to the optional therapeutic window were randomized to receive upfront methotrexate over 4 or 24 hours. Four days after methotrexate treatment, remission induction therapy began with prednisone, vincristine, daunorubicin, and asparaginase (Table 1). Patients with ≥ 1% MRD on day 19 received three additional doses of asparaginase. Subsequent induction therapy consisted of cyclophosphamide, mercaptopurine and cytarabine. Upon hematopoietic recovery (between days 43 and 46), MRD was assessed, and consolidation therapy began (Table 1).
Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C., Ribeiro R.C., Rubnitz J.E., Raimondi S.C., Onciu M., Coustan-Smith E., Kun L.E., Jeha S., Cheng C., Howard S.C., Simmons V., Bayles A., Metzger M.L., Boyett J.M., Leung W., Handgretinger R., Downing J.R., Evans W.E, & Relling M.V. (2009). Treatment of Childhood Acute Lymphoblastic Leukemia Without Prophylactic Cranial Irradiation. The New England journal of medicine, 360(26), 2730-2741.
Publication 2009
Asparaginase Cyclophosphamide Cytarabine Daunorubicin Hematopoietic System Mercaptopurine Methotrexate Neoadjuvant Therapy Patients Prednisone Remission Induction Therapeutics Vincristine
4
Continuation Therapy Protocol for Pediatric Leukemia
Cited 15 times
During initial continuation therapy (Table 1), low-risk cases received daily mercaptopurine and weekly methotrexate with pulses of mercaptopurine, dexamethasone and vincristine. Two reinduction treatments were given between weeks 7–9 and weeks 17–19. Standard-risk cases received weekly asparaginase and daily mercaptopurine with pulses of doxorubicin plus vincristine plus dexamethasone. They also received two reinduction treatments between weeks 7–9 and weeks 17–20.
For the remaining continuation therapy (Supplementary Table 1), low-risk patients received mercaptopurine and methotrexate, with pulses of dexamethasone, vincristine and mercaptopurine, and standard-risk patients received three rotating drug pairs (mercaptopurine plus methotrexate, cyclophosphamide plus cytarabine, and dexamethasone plus vincristine). Dosages of mercaptopurine and methotrexate were adjusted according to the tolerance, and thiopurine methyltransferase phenotype and genotypes.17 (link) Total scheduled dosages of anthracyclines and cyclophosphamide were limited to 110 mg/m2 and 230 mg/m2, and 1 g/m2 and 4.6 g/m2, for low-risk and standard-risk patients, respectively. Continuation treatment lasted 120 weeks in girls and 146 weeks in boys.
Pui C.H., Campana D., Pei D., Bowman W.P., Sandlund J.T., Kaste S.C., Ribeiro R.C., Rubnitz J.E., Raimondi S.C., Onciu M., Coustan-Smith E., Kun L.E., Jeha S., Cheng C., Howard S.C., Simmons V., Bayles A., Metzger M.L., Boyett J.M., Leung W., Handgretinger R., Downing J.R., Evans W.E, & Relling M.V. (2009). Treatment of Childhood Acute Lymphoblastic Leukemia Without Prophylactic Cranial Irradiation. The New England journal of medicine, 360(26), 2730-2741.
Publication 2009
Anthracyclines Asparaginase Boys Cyclophosphamide Cytarabine Dexamethasone Genotype Immune Tolerance Mercaptopurine Methotrexate Patients Pharmaceutical Preparations Phenotype Pulses thiopurine S-methyltransferase VAD I protocol Vincristine Woman
5
Comprehensive LLPS Protocol Database
Cited 13 times
All LLPS data in LLPSDB were curated manually from literatures. The literature mining was performed via retrieving in ‘PubMed’ and ‘Web of Science’ by key words: phase separation, phase transition, liquid, protein, de-mixing, assembly, condensate, condensation, coacervate, segregate and segregation. From the total retrieved 3603 papers published up to July 2019, 154 articles were screened out. Only original research articles were collected, and those containing the data of LLPS in vitro were retained. Review papers were excluded to avoid redundancy and confusion. We considered proteins and nucleic acids involved in LLPS as ‘main components’, and constructed entries accordingly. Each entry was identified based on specific protein sequence and nucleic acid type (such as the wild type and mutant of FUS belong to different entry, similarly, component of RNA with 15nt and that with 30nt belong to different entry). Other molecules such as salts, buffer molecules and crowding agents, along with temperature and pH, etc., were considered as experimental conditions. These conditions, in their original units of measurement in the paper, together with the detected phase behavior (a detailed phase diagram or a tag ‘Yes’ or ‘No’ for whether the system phase separates or not) were extracted manually from the screened articles. All the data were checked at least twice. Any incomplete/ambiguous entry was consolidated either by contacting the authors of the article or tracking related references. All the specific information extracted from literatures is listed in the top box of Figure 1.
In LLPSDB, some protein annotations (mainly for natural proteins) such as localization, Gene Ontology (GO) term and sequences of some proteins (if not provided by the literature), were obtained from UniProt/NCBI. As IDRs and LCRs in proteins have been demonstrated to be generally critical in LLPS, the sequences of them are presented in visualization. IDRs were identified via searching MobiDB (28 (link)) or by PONDR VL3-BA algorithm (33 (link)) for those sequences not deposited in MobiDB, and only those segments with no fewer than 15 residues were taken into account (33 (link)). LCRs data were also from MobiDB or predicted by SEG algorithm (34 (link)) with default parameters. Additionally, in order to organize the data methodically, other information such as protein type (natural or designed), protein structure type (IDR, IDR-fold or Fold) and main components (whether DNAs or RNAs are included) were annotated. Other databases related with the corresponding protein, such as DisProt (27 (link)), OMIM (29 (link)), IDEAL (30 (link)), AmyPro (31 (link)), FuzzDB (32 (link)), as well as the PMID/DOI of the literature, were also linked from LLPSDB.
It is important to emphasize that LLPSDB focuses on situations where protein alone or with other components (proteins or nucleic acids) was validated to undergo LLPS (or NOT) in vitro. Since in many investigated systems, the mixtures of RNA such as total mRNAs (35 (link),36 (link)), instead of specific nucleic acid were added, the sequences of nucleic acid are not presented in LLPSDB. Those systems with only nucleic acids as main component (which means there is no protein) in solution were not included. In addition, systems with segregation of antibodies (such as IgG) and materials designed as drug carrier were also excluded. LLPSDB contains systems where the condensates were observed to flow, fuse, drop, wet and reverse (which were characterized as typical liquid-like droplets), or in which liquid morphology was identified by FRAP (fluorescence recovery after photobleaching), EM (electron microscopy) or other techniques. Systems in which assemblies change morphology from liquid in ripening, such as droplet-to-gel or droplet-to-aggregate were recorded in the database, but those form gels or aggregates directly from homogeneous solution were not deposited.
Li Q., Peng X., Li Y., Tang W., Zhu J., Huang J., Qi Y, & Zhang Z. (2019). LLPSDB: a database of proteins undergoing liquid–liquid phase separation in vitro. Nucleic Acids Research, 48(D1), D320-D327.
Publication 2019
Amino Acid Sequence Antibodies Base Sequence Buffers DNA Drug Carriers Electron Microscopy Gels Nucleic Acids Phase Transition Protein Annotation Proteins RNA, Messenger Salts Vincristine

Most recents protocols related to «Vincristine»

1
Treatment of Pediatric Wilms Tumor
Not available on PMC !

Example 9

A pediatric patient with Stage IV Wilms tumor is treated with dactinomycin, doxorubicin, cyclophosphamide and vincristine for 65 weeks. Doses of the drugs are as follows: dactinomycin (15 mcg/kg/d [IV]), vincristine (1.5 mg/m 2 wk [IV)), Adriamycin (doxorubicin 20 mg/m2/d [IV]), and cyclophosphamide (10 mg/kg/d [IV]). Dactinomycin courses are given postoperatively and at 13, 26, 39, 52, and 65 weeks. Vincristine is given on days 1 and 8 of each Adriamycin course. Adriamycin is given for three daily doses at 6, 19, 32, 45, and 58 weeks. Cyclophosphamide is given for three daily doses during each Adriamycin and each dactinomycin course except the postoperative dactinomycin course. During each administration of dactinomycin and vincristine a dose of 0.2 cc/kg of DDFPe is administered while the patient breathes supplemental oxygen. *D'angio, Giulio J., et al. “Treatment of Wilms' tumor. Results of the third national Wilms' tumor study.” Cancer 64.2 (1989): 349-360.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Patent 2024
Adriamycin Cyclophosphamide Dactinomycin Doxorubicin Malignant Neoplasms Nephroblastoma Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Vincristine
2
Enhancing Rhabomyosarcoma Treatment
Not available on PMC !

Example 6

An adult patient with rhabomyosarcoma is treated with IV Vincristine at a dose of 1.4 mg/m2. Concomitantly the patient is administered 0.1 cc kg of DDFPc while breathing room air. Despite breathing room air, increased oxygen levels am still attained in the tumor tissue resulting in increased activity of the drug.

US11857627B2. Fractionated radiotherapy and chemotherapy with an oxygen therapeutic (2024-01-02). NuvOx Pharma LLC [US]. Inventors: Evan C. Unger [US].
Patent 2024
Adult Neoplasms Oxygen Patients Pharmaceutical Preparations Pharmacotherapy Radiotherapy Therapeutics Tissues Vincristine
3
Gastric MALT Lymphoma Treatment Protocol
The primary therapeutic modalities were determined using the Lugano and Paris staging system (Online Resource 1) and the HPI status. H. pylori eradication was performed in all patients with HPI and localized stage gastric MALT lymphoma. For first-line eradication therapy, a proton pump inhibitor (PPI)-based triple therapy regimen was administered for 2 weeks: PPI (standard dose twice a day), clarithromycin (0.5 g twice a day), and amoxicillin (1 g twice a day). 13C urea breath tests were performed in all patients for 3 months or at least 8 weeks after treatment completion, and at least 2 weeks after PPI withdrawal to confirm HPI eradication. For patients who failed first-line triple therapy, a second-line quadruple-therapy regimen consisting of PPI (standard dose twice a day), tripotassium dicitrato bismuthate (300 mg four times a day), metronidazole (500 mg thrice a day), and tetracycline (500 mg four times a day) was administered for 1–2 weeks.
Patients received radiotherapy, chemotherapy, or chemoradiotherapy if they did not achieve lymphoma regression following first- and second-line HPI eradication therapy, or were at the localized stage without initial HPI, or had advanced-stage gastric MALT lymphoma. For radiotherapy, the clinical target volume included the entire stomach and regional lymph nodes and was prescribed as 30.6 Gy over 17 fractions on the stomach [20 (link)]. The internal target volume (ITV) and planning target volume were set using the motion information obtained from the 4-dimensional CT for assessment of breathing motions and defined as an expansion of 5 mm from the ITV considering the set-up error of the patient [20 (link)]. Patients with the involvement of ≥ 2 organs were excluded from radiotherapy. The R-CVP was the primary systemic chemotherapy regimen, consisting of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2, and vincristine 1.4 mg/m2 on day 1, and prednisolone 60 mg/m2 on days 1–5 every 21 days. Localized stage lesions involving small-sized mucosal layers in patients with initial HPI-negative findings could be selectively treated by endoscopic mucosal resection (EMR) and close observation. In the case of chemoradiotherapy, we only used additional radiotherapy for consolidation purposes after chemotherapy by the physicians’ decision. To investigate the side effects of each treatment modality, we reviewed the medical records following the National Cancer Institute’s Common Terminology Criteria for Adverse Events version 5.0.
Min G.J., Kang D., Lee H.H., Kim S.J., Kim T.Y., Jeon Y.W., O J.H., Choi B.O., Park G, & Cho S.G. (2023). Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience. Annals of Hematology, 102(4), 877-888.
Publication 2023
Aftercare Amoxicillin bismuth subcitrate Breath Tests Chemoradiotherapy Clarithromycin Cyclophosphamide Gastric lymphoma Helicobacter pylori Lymphoma Metronidazole Mucous Membrane Nodes, Lymph Patient Participation Patients Pharmacotherapy Physicians Prednisolone Proton Pump Inhibitors Radiotherapy Resection, Endoscopic Mucosal Rituximab Stomach Tetracycline Treatment Protocols Urea Vincristine
4
High-throughput Drug Screening in HepG2 Cells
HepG2 or HB214 (1500 cells/well) was seeded on a 384 well plate in 30 μl. Drugs were added after 24 h. Cell Titer Glo (CTG) viability assay was conducted after 72 h of drug treatment. Briefly, CellTiter-Glo 2.0 (#G9243 Promega) was added to each well in a 1:1 v/v ratio. Plates were then covered to keep from light and incubated at RT on an orbital shaker at 150 RPM for 30 mins. After the incubation, plate was read on a synergy H4 plate reader for luminescence. Dose effect curves for each drug were calculated using Prism software, version 9 (GraphPad). For drug combinations, responses were analyzed using SynergyFinder2.050 (link). Drugs used include cisplatin (#479036-5 G, Sigma Aldrich), gemcitabine (#AC456890010, Fisher Scientific), vincristine (#AAJ60907MA, Fisher Scientific), triapine (#50-136-4826, Fisher Scientific), MK1775 (#M4102, LKT laboratories, Saint Paul, Minnesota), doxorubicin (#BP25161, Fisher Scientific), sorafenib (#NC0749948, Fisher Scientific), SN-38 (#S4908-50MG, Selleck Chemicals, Harris County, Texas), deferoxamine mesylate (#AC461770010, Acros Organics, Geel, Belgium), KU60019 (#S1570, Selleck Chemicals). All concentrations were seeded in triplicate and the experiment was repeated three times. Significance was determined using the Extra Sum of Squares f test.
Brown A., Pan Q., Fan L., Indersie E., Tian C., Timchenko N., Li L., Hansen B.S., Tan H., Lu M., Peng J., Pruett-Miller S.M., Yu J., Cairo S, & Zhu L. (2023). Ribonucleotide reductase subunit switching in hepatoblastoma drug response and relapse. Communications Biology, 6, 249.
Publication 2023
3-aminopyridine-2-carboxaldehyde thiosemicarbazone Biological Assay Cells Cell Survival Cisplatin Doxorubicin Drug Combinations Gemcitabine KU 60019 Light Luminescence Mesylate, Deferoxamine MK-1775 Pharmaceutical Preparations prisma Promega SN 38 Sorafenib Vincristine
5
Anemia in Acute ATLL Patients
We analyzed patients with acute or lymphoma-type ATLL who were diagnosed at our hospital between 2014 and 2020 and underwent initial treatment with a CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-based chemotherapy regimen. Patients who received mogamulizumab in combination with CHOP therapy were also included in this analysis. Patients with any of the following histories were excluded: 1) receiving any anti-cancer drugs, immunosuppressants, or radiation therapy within the last five years; and 2) having any serious infectious diseases within the past 12 months. We also excluded patients with iron or vitamin deficiencies at the time of initial diagnosis. To minimize the effect of anticancer drugs on hematopoiesis and RBC morphology, peripheral blood smears and laboratory data were collected within two weeks of treatment intervention. Based on past clinical observations, these two weeks was the time when the actual major changes in RBC morphology have been observed. Blood smears were collected exclusively from the patients with acute-type ATLL who were available for the appraisable peripheral blood smears and were evaluated by a physician and authorized laboratory technologists. Data on the peripheral blood cell count, mean corpuscular volume (MCV), red cell distribution width (RDW), hemoglobin (Hb), lactate dehydrogenase (LDH), and soluble interleukin-2 receptor (sIL-2R) were collected, and the trends of these data over time were examined. To examine the factors influencing the progression of anemia, the association between the degree of progression of anemia and LDH, sIL2R, and RDW was statistically analyzed. Statistical analyses were conducted using the Shapiro test and cor test functions of R version 4.2.0.
Obama K., Nakabeppu S, & Inoue H. (2023). Red Blood Cell Deformation and Progressive Anemia Following Therapeutic Intervention in Patients With Adult T-Cell Leukemia/Lymphoma. Cureus, 15(2), e34641.
Publication 2023
Anemia Antineoplastic Agents BLOOD Blood Cell Count Communicable Diseases Cyclophosphamide DDIT3 protein, human Diagnosis Disease Progression Doxorubicin Erythrocyte Volume, Mean Cell Hematopoiesis Hemoglobin Immunosuppressive Agents Interleukin 2 Receptor Iron Lactate Dehydrogenase Lymphoma mogamulizumab Patients Pharmacotherapy Physicians Prednisone Radiotherapy Red Cell Distribution Width T-Cell Leukemia-Lymphomas, Adult Treatment Protocols Vincristine Vitamin Deficiency

Top products related to «Vincristine»

1
Vincristine by Merck Group
Sourced in United States, Germany, United Kingdom, Sao Tome and Principe, France
Vincristine is a laboratory reagent used in various research and analytical applications. It is a naturally-derived compound extracted from the Catharanthus roseus plant. Vincristine exhibits anti-tumor and anti-mitotic properties, making it a valuable tool for researchers studying cell biology and cancer-related processes. The core function of Vincristine is to inhibit microtubule formation, which is essential for cell division and proliferation.
2
Paclitaxel by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Macao, Japan, Sao Tome and Principe, Canada, Poland, Spain, Israel, Australia, Switzerland, Italy
Paclitaxel is a pharmaceutical compound used in the production of various cancer treatment medications. It functions as a microtubule-stabilizing agent, which plays a crucial role in the development and regulation of cells. Paclitaxel is a key ingredient in the manufacture of certain anti-cancer drugs.
3
Doxorubicin by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, India, Italy, Poland, Macao, Japan, Sao Tome and Principe, Canada, Spain, Brazil, Australia, Belgium, Switzerland, Singapore, Israel
Doxorubicin is a cytotoxic medication that is commonly used in the treatment of various types of cancer. It functions as an anthracycline antibiotic, which works by interfering with the DNA replication process in cancer cells, leading to their destruction. Doxorubicin is widely used in the management of different malignancies, including leukemia, lymphoma, and solid tumors.
4
Vincristine by Selleck Chemicals
Sourced in United States
Vincristine is a laboratory chemical compound used in various research and analytical applications. It serves as a standard reference material and is commonly employed in chemical analysis and testing procedures.
5
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
6
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
7
Verapamil by Merck Group
Sourced in United States, Germany, France, United Kingdom, China, Japan, Spain, Italy, Sao Tome and Principe, Switzerland, Australia, Ireland, Belgium
Verapamil is a laboratory product manufactured by Merck Group. It is a calcium channel blocker that inhibits the movement of calcium ions through cell membranes, which can affect various physiological processes. The core function of Verapamil is to serve as a research tool for the study of calcium-dependent mechanisms in biological systems.
8
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
9
Etoposide by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, France, China, Italy, Canada, Switzerland, Belgium, Macao, Portugal, Poland
Etoposide is a chemotherapeutic agent used in the treatment of various types of cancer. It is a topoisomerase inhibitor that disrupts the process of DNA replication, leading to cell death. Etoposide is available as a solution for intravenous administration.
10
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.

More about "Vincristine"

Vincristine, a chemotherapeutic agent derived from the periwinkle plant (Catharanthus roseus), is widely used in the treatment of various cancers, including leukemia, lymphoma, and solid tumors.
This potent antineoplastic drug works by disrupting the mitotic spindle, leading to cell cycle arrest and apoptosis.
When used effectively, vincristine can provide significant therapeutic benefits, but it requires careful dosing and monitoring to balance its efficacy and potential side effects, such as neurotoxicity, myelosuppression, and constipation.
Researchers can leverage the power of PubCompare.ai, an AI-driven platform, to optimize their vincristine research.
This innovative tool enables them to identify the most effective protocols and products from the scientific literature, preprints, and patents, enhancing the reproducibility and accuracy of their studies.
By harnessing the power of AI-driven comparisons, researchers can uncover new insights and drive their vincristine research forward, exploring synergistic effects with other chemotherapeutic agents like paclitaxel, doxorubicin, cisplatin, and etoposide, as well as the use of adjuvants like DMSO and verapamil to improve drug delivery and efficacy.
Optimizing vincristine research is crucial for advancing cancer treatment and improving patient outcomes.
PubCompare.ai provides researchers with a powerful tool to navigate the vast array of scientific information, identify the most promising approaches, and ultimately, develop more effective and safer vincristine-based therapies.
Whether working with vincristine alone or in combination with other drugs, this AI-driven platform can be a game-changer in the field of oncology research.